Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Early-stage Operable Non Small Cell Lung Cancer”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Ended earlyNCT01138722
What this trial is testing

Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial

Who this might be right for
Early Stage Non-small Cell Lung Cancer
University Hospital, Ghent 1
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06694454
What this trial is testing

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small Cell LungNon-Small Cell Lung Carcinoma+2 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Study completedNCT04271384
What this trial is testing

Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer Stage I
Hospital Israelita Albert Einstein 25
Large-scale testing (Phase 3)Looking for participantsNCT06284317
What this trial is testing

Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Who this might be right for
Non Small Cell Lung Cancer
ETOP IBCSG Partners Foundation 290
Testing effectiveness (Phase 2)Study completedNCT00191763
What this trial is testing

Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell-Lung Cancer
Eli Lilly and Company 52
Testing effectiveness (Phase 2)UnknownNCT04638582
What this trial is testing

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Lung Cancer, Nonsmall Cell
McGill University Health Centre/Research Institute of the McGill University Health Centre 44
Not applicableLooking for participantsNCT07008742
What this trial is testing

Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEarly-stage Operable Non Small Cell Lung CancerNon Small Cell Lung Cancer+3 more
Royal Marsden NHS Foundation Trust 100
Not applicableUnknownNCT03771404
What this trial is testing

NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy"

Who this might be right for
Non Small Cell Lung Cancer
Hellenic Oncology Research Group 50
Large-scale testing (Phase 3)Active Not RecruitingNCT03833154
What this trial is testing

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 724